Positron Sees Global Growth in Nuclear Cardiology and Announces Pulse CDCC(R) Sale to Pakistan Institute

Positron Corporation (OTCBB:POSC) a molecular imaging solutions company focused on Nuclear Cardiology, announces the sale of a Pulse CDCC(R) camera to CPE Institute Of Cardiology in Multan, Pakistan.

The Pulse CDCC(R), a compact digital cardiac camera (SPECT camera), with a robust cardiac specific, imaging software package designed to ensure effortless interpretation for today's most challenging clinical cases. In the past 6 months, Positron has seen an increase in the global demand of nuclear cardiology and imaging devices. There has been great interest from Asia and the Middle East in SPECT imaging, in specific Positron's Pulse CDCC(R) camera.

Joseph Oliverio, Chief Technical Officer stated, "From a technical design perspective, the Pulse CDCC(R) is a great workhorse cardiac camera and the right choice for cardiology offices and hospital departments in today's economic climate. The electronic and mechanical aspects were designed to ensure a cohesive camera system with superior performance and reliability at an affordable price. We have more than 100 PULSE cameras all over the world and have expanded our focus to the global marketplace for our SPECT camera. We are pleased to be working with CPE Institute of Cardiology in Pakistan and that they selected Positron for their nuclear cardiology needs."

About Positron:

Positron is a molecular imaging company focused on Nuclear Cardiology. Positron utilizes its proprietary product line to provide unique solutions to the Nuclear Medicine community ranging from imaging to radiopharmaceutical distribution. Positron products include: the Attrius(TM), a PET imaging device; the Pulse(R), a SPECT imaging device; the Nuclear Pharm-Assist(R), an automated radiopharmaceutical distribution device; and the Tech-Assist(TM), a radiopharmaceutical injection shield. More information about Positron is available at www.positron.com.

Forward Looking Statements:

Statements in this document contain certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended. These statements are based on many assumptions and estimates and are not guarantees of future performance and may involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Positron Corporation to be materially different from future results, performance or achievements expressed or implied by such forward-looking statements. Our actual results may differ materially from the results anticipated in these forward-looking statements due to a variety of factors, including, without limitation those set forth as "Risk Factors" in our filings with the Securities and Exchange Commission.

For further information, please contact Positron Corporation at (317)576-0183.

SOURCE: Positron Corporation

Positron Corporation 
Joseph Oliverio, 317-576-0183

Related terms: asia, clinical, community, hospital, medicine, nuclear, pakistan, products, software